These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 26871948)

  • 21. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
    Lan H; Zhang W; Jin K; Liu Y; Wang Z
    Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanotechnology synergized immunoengineering for cancer.
    Chauhan DS; Dhasmana A; Laskar P; Prasad R; Jain NK; Srivastava R; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharm Biopharm; 2021 Jun; 163():72-101. PubMed ID: 33774162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boosting Checkpoint Immunotherapy with Biomaterials.
    Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
    ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer.
    Cheng CT; Castro G; Liu CH; Lau P
    Clin Chim Acta; 2019 May; 492():12-19. PubMed ID: 30711524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomaterials for Personalized Cell Therapy.
    Facklam AL; Volpatti LR; Anderson DG
    Adv Mater; 2020 Apr; 32(13):e1902005. PubMed ID: 31495970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.
    Ruan S; Huang Y; He M; Gao H
    Adv Sci (Weinh); 2022 May; 9(16):e2200027. PubMed ID: 35343112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomaterial-Based Implantable Devices for Cancer Therapy.
    Chew SA; Danti S
    Adv Healthc Mater; 2017 Jan; 6(2):. PubMed ID: 27886461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunologically active biomaterials for cancer therapy.
    Ali OA; Mooney DJ
    Curr Top Microbiol Immunol; 2011; 344():279-97. PubMed ID: 20556594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnology-based immunotherapies to combat cancer metastasis.
    Zhao Y; Bilal M; Qindeel M; Khan MI; Dhama K; Iqbal HMN
    Mol Biol Rep; 2021 Sep; 48(9):6563-6580. PubMed ID: 34424444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing the immune system for cancer therapy.
    Smith EL; Zamarin D; Lesokhin AM
    Curr Opin Oncol; 2014 Nov; 26(6):600-7. PubMed ID: 25250678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine immunotherapy in lung cancer: Clinical experience and future directions.
    Freeman-Keller M; Goldman J; Gray J
    Pharmacol Ther; 2015 Sep; 153():1-9. PubMed ID: 25989231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving cancer immunotherapy through nanotechnology.
    Goldberg MS
    Nat Rev Cancer; 2019 Oct; 19(10):587-602. PubMed ID: 31492927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses.
    Chen Q; Chen M; Liu Z
    Chem Soc Rev; 2019 Nov; 48(22):5506-5526. PubMed ID: 31589233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.
    Shah SA; Oakes RS; Jewell CM
    Adv Drug Deliv Rev; 2024 Jun; 209():115315. PubMed ID: 38670230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing biomaterial architecture to drive anticancer innate immunity.
    Davis MA; Cho E; Teplensky MH
    J Mater Chem B; 2023 Nov; 11(46):10982-11005. PubMed ID: 37955201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.
    Wang C; Ye Y; Hu Q; Bellotti A; Gu Z
    Adv Mater; 2017 Aug; 29(29):. PubMed ID: 28556553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.
    Andorko JI; Hess KL; Jewell CM
    AAPS J; 2015 Mar; 17(2):323-38. PubMed ID: 25533221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering Immune Tolerance with Biomaterials.
    Gammon JM; Jewell CM
    Adv Healthc Mater; 2019 Feb; 8(4):e1801419. PubMed ID: 30605264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precise modulation and use of reactive oxygen species for immunotherapy.
    Li X; Gao J; Wu C; Wang C; Zhang R; He J; Xia ZJ; Joshi N; Karp JM; Kuai R
    Sci Adv; 2024 May; 10(20):eadl0479. PubMed ID: 38748805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinatorial prospects of nano-targeted chemoimmunotherapy.
    Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
    Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.